IMA
ImageneBio Inc
NASDAQ · Healthcare · Biotechnology · US
$4.85
−0.72%Income statement
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Revenue | |||||
| Total Revenue | — | 800.0K | 3.5M | 9.2M | 15.6M |
| Cost of Revenue | 735.0K | 1.0M | 1.5M | 1.0M | 64.3M |
| Gross Profit | (735.0K) | (233.0K) | 2.0M | 8.1M | (48.7M) |
| Operating Expenses | |||||
| R&D Expense | 33.4M | 28.5M | 32.1M | 59.7M | 64.3M |
| SG&A Expense | 21.9M | 20.7M | 8.4M | 24.9M | 22.2M |
| General & Admin Expense | 21.9M | 20.7M | 8.4M | 24.9M | 22.2M |
| Selling & Marketing Expense | — | — | — | — | — |
| Other Expenses | 2.9M | (1.0M) | (1.5M) | (1.0M) | (64.3M) |
| Total Operating Expenses | 58.2M | 48.2M | 39.0M | 83.6M | 22.2M |
| Cost and Expenses | 59.0M | 49.3M | 40.5M | 84.6M | 86.5M |
| Operating Income (EBIT) | (59.0M) | (48.5M) | (37.0M) | (75.4M) | (70.9M) |
| Non-Operating | |||||
| Interest Income | 6.0M | 2.0M | 7.4M | 7.1M | 2.1M |
| Interest Expense | 96.0K | — | — | — | — |
| Net Interest Income | 5.9M | 2.0M | 7.4M | 7.1M | 2.1M |
| Other Non-Op Income/Expense | 6.2M | 2.8M | 445.0K | 7.1M | 2.1M |
| Non-Operating Income (excl Interest) | (4.8M) | (2.8M) | (445.0K) | (7.1M) | (2.1M) |
| EBT (Pre-Tax Income) | (52.8M) | (45.7M) | (36.6M) | (68.3M) | (68.8M) |
| Income Tax Expense | (324.0K) | (350.0K) | 13.0K | (162.0K) | — |
| Bottom Line | |||||
| Net Income | (52.5M) | (45.3M) | (36.6M) | (68.2M) | (68.8M) |
| Earnings from Cont. Ops | (52.5M) | (45.3M) | (36.6M) | (68.2M) | (68.8M) |
| Earnings from Discont. Ops | — | — | — | — | — |
| Bottom Line Net Income | (53.3M) | (52.4M) | (48.4M) | (68.2M) | (68.8M) |
| Per Share | |||||
| Basic EPS | ($5.21) | ($9.64) | ($40.52) | ($19.60) | ($22.80) |
| Diluted EPS | ($5.21) | ($9.64) | ($40.52) | ($19.60) | ($22.80) |
| Revenue Per Share | $0.00 | $0.15 | $2.93 | $2.63 | $5.18 |
| Shares | |||||
| Basic Shares Outstanding | 16.2M | 5.4M | 1.2M | 3.5M | 3.0M |
| Diluted Shares Outstanding | 16.2M | 5.4M | 1.2M | 3.5M | 3.0M |
| Profitability Metrics | |||||
| EBITDA | (52.8M) | (44.7M) | (35.0M) | (67.3M) | (68.0M) |
| D&A | 1.4M | 1.0M | 1.5M | 1.0M | 751.0K |
| EBIT | (54.2M) | (45.7M) | (36.6M) | (68.3M) | (68.8M) |
As reported, in the filing currency · TTM sums the four latest quarters; MRQ is the latest quarter · Negatives in parentheses; a dash is a line the filing does not carry · Data as of Jun 1, 2026